Promising trial of drug to treat low grade serous ovarian cancer

29 September 2019

There have been promising results from a trial for low grade ovarian cancer, revealed at the ESMO conference 2019 (European Society for Medical Oncology).

The randomised trial of a drug called trametinib – previously used to treat melanoma – was shown to have an increased response rate compared with standard treatments.

Comments (0)

Please verify your action

Comment (maximum 3500 characters) (required)

Add a picture

Notify me when someone makes a comment

First name (required)

Last name (required)

Email (required)

Which country do you live in?

Postcode (required)

Address line 1

Address line 2

Town or city

Keeping In Touch

We would love to keep you posted with news, activities and how you can help in other ways. We'll never sell or swap your details with anybody else. You are free to change your mind at any time. Please tick the boxes below to opt in to receive communications from Ovacome by email, SMS, telephone, and/or post.

Via email

Via telephone

Via SMS

Via post

Which country do you live in?

Postcode (required)

Address line 1

Address line 2

Town or city

Your Privacy

We will always store your personal details securely. We'll use them to provide the service that you have requested, and communicate with you in the way(s) that you have agreed to. Your data may also be used for analysis purposes, to help us provide the best service possible. For full details see our Privacy Policy.

By submitting this form you are agreeing to our terms and conditions

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.